Ian Adatia

TL;DR: In this paper, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches, and the main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups.

TL;DR: A panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension.

TL;DR: Inhaled nitric oxide is a potent pulmonary vasodilator after CPB with minimal systemic circulatory effects and is consistent with the purported role of cGMP as the second messenger effecting smooth muscle relaxation in this process.

TL;DR: Although a lack of clinical trial data for the use of PAH-targeted therapy persists, emerging data are improving the identification of appropriate targets for goal-oriented therapy in children, and will likely improve future clinical trial design to enhance outcomes in paediatric PAH.

TL;DR: The role of nitrite and nitrate assays (alongside direct measurements of nitric oxide in breath) may be restricted to the monitoring of disease progression, or response to therapy in individual patients or subgroups.